|
骨科儿科公司
|
| |
![]() |
|
| | | | | | | | | | | | | |
| | |
每股
|
| |
共计
|
| ||||||
公开发行价格 | | | | $ | | | | | $ | | | ||
承保折扣(1) | | | | $ | | | | | | $ | | | |
除支出外,还向矫形儿科公司收取款项。 | | | | $ | | | | | | $ | | | |
在支出前出售股东的收益 | | | | $ | | | | | | $ | | | |
| | | | | | | | | | | | | |
| 派珀·贾弗雷 | | | | | |
|
|
| BTIG | | |
JMP证券
|
| |
SunTrust Robinson Humphrey
|
|
| | |
页
|
| |||
招股章程补充
|
| | | | | | |
关于本招股说明书的补充
|
| | | | S-II | | |
关于前瞻性语句的特别说明
|
| | | | S-III | | |
招股说明书补充摘要
|
| | | | S-1 | | |
危险因素
|
| | | | S-14 | | |
收益的使用
|
| | | | S-20 | | |
稀释
|
| | | | S-21 | | |
红利政策
|
| | | | S-22 | | |
大写
|
| | | | S-23 | | |
出售股东
|
| | | | S-24 | | |
美国联邦所得税对非美国国有股持有者的影响
|
| | | | S-25 | | |
承保
|
| | | | S-30 | | |
法律事项
|
| | | | S-37 | | |
专家
|
| | | | S-37 | | |
在其中可以找到更多信息
|
| | | | S-37 | | |
引用注册
|
| | | | S-37 | | |
招股说明书 | | | |||||
关于这份招股说明书
|
| | | | 1 | | |
在其中可以找到更多信息
|
| | | | 2 | | |
引用注册
|
| | | | 3 | | |
公司
|
| | | | 4 | | |
根据本招股说明书提供的产品
|
| | | | 7 | | |
危险因素
|
| | | | 8 | | |
关于前瞻性语句的特别说明
|
| | | | 9 | | |
收益的使用
|
| | | | 10 | | |
股本描述
|
| | | | 11 | | |
债务证券的描述
|
| | | | 16 | | |
认股权证
的描述
|
| | | | 23 | | |
证券的合法所有权
|
| | | | 25 | | |
出售股东
|
| | | | 28 | | |
分配计划
|
| | | | 29 | | |
法律事项
|
| | | | 31 | | |
专家
|
| | | | 31 | | |
| | |
截至12月31日的年度,
|
| |
截至9月30日的9个月,
|
| ||||||||||||||||||||||||
| | | | | | | | | | | | | | | | | | | | |
(未经审计)
|
| |||||||||
(以千计,除股份及每股外)
资料) |
| |
2016
|
| |
2017
|
| |
2018
|
| |
2018
|
| |
2019
|
| |||||||||||||||
业务报表数据: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
净收入
|
| | | $ | 37,298 | | | | | $ | 45,620 | | | | | $ | 57,559 | | | | | $ | 42,991 | | | | | $ | 53,600 | | |
收入成本
|
| | | | 10,931 | | | | | | 11,170 | | | | | | 14,879 | | | | | | 10,825 | | | | | | 13,431 | | |
毛利
|
| | | | 26,367 | | | | | | 34,450 | | | | | | 42,680 | | | | | | 32,166 | | | | | | 40,169 | | |
业务费用: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
销售和营销
|
| | | | 16,661 | | | | | | 20,527 | | | | | | 26,563 | | | | | | 20,005 | | | | | | 22,924 | | |
一般和行政
|
| | | | 11,631 | | | | | | 16,972 | | | | | | 20,938 | | | | | | 16,393 | | | | | | 19,448 | | |
首次公开发行成本
|
| | | | 1,979 | | | | | | − | | | | | | − | | | | | | − | | | | | | − | | |
研发
|
| | | | 2,223 | | | | | | 3,423 | | | | | | 4,732 | | | | | | 3,455 | | | | | | 3,843 | | |
业务费用共计
|
| | | | 32,494 | | | | | | 40,922 | | | | | | 52,233 | | | | | | 39,853 | | | | | | 46,215 | | |
营运损失
|
| | | | (6,127) | | | | | | (6,472) | | | | | | (9,553) | | | | | | (7,687) | | | | | | (6,046) | | |
其他费用: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
利息费用
|
| | | | 1,476 | | | | | | 2,490 | | | | | | 2,255 | | | | | | 1,722 | | | | | | 2,232 | | |
其他费用(收入)
|
| | | | (1,031) | | | | | | (30) | | | | | | 217 | | | | | | 148 | | | | | | 78 | | |
其他费用共计
|
| | | | 445 | | | | | | 2,460 | | | | | | 2,472 | | | | | | 1,870 | | | | | | 2,310 | | |
持续业务净亏损
|
| | | | (6,572) | | | | | | (8,932) | | | | | | (12,025) | | | | | | (9,557) | | | | | | (8,356) | | |
从停止作业中获得的收益
|
| | | | − | | | | | | − | | | | | | − | | | | | | − | | | | | | 54 | | |
净损失
|
| | | $ | (6,572) | | | | | $ | (8,932) | | | | | $ | (12,025) | | | | | $ | (9,557) | | | | | $ | (8,302) | | |
可归因于普通股股东的净亏损
|
| | | $ | (12,448) | | | | | $ | (23,530) | | | | | $ | (12,025) | | | | | $ | (9,557) | | | | | $ | (8,302) | | |
加权平均股票 - 基本和稀释
|
| | | | 1,744,356 | | | | | | 4,017,330 | | | | | | 12,567,387 | | | | | | 12,417,972 | | | | | | 14,487,015 | | |
普通股股东每股净亏损(1):
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
碱性稀释
|
| | | $ | (7.14) | | | | | $ | (5.86) | | | | | $ | (0.96) | | | | | $ | (0.77) | | | | | $ | (0.57) | | |
|
| | |
截至2019年9月30日
|
| |||||||||
(单位:千)
|
| |
实际
|
| |
调整数(1)
|
| ||||||
资产负债表数据: | | | | | | | | | | | | | |
现金
|
| | | $ | 19,669 | | | | | $ | | | |
周转资金(2)
|
| | | | 62,536 | | | | | | | | |
总资产
|
| | | | 153,424 | | | | | | | | |
长期负债总额
|
| | | | 21,135 | | | | | | | | |
负债总额
|
| | | | 67,319 | | | | | | | | |
股东权益总额
|
| | | | 86,105 | | | | | | | | |
| | |
三个月结束
九月三十日 |
| |
九个月结束
九月三十日 |
| ||||||||||||||||||
| | |
(未经审计)
(单位:千) |
| |||||||||||||||||||||
| | |
2019
|
| |
2018
|
| |
2019
|
| |
2018
|
| ||||||||||||
持续业务净亏损
|
| | | $ | (2,877) | | | | | $ | (1,865) | | | | | $ | (8,356) | | | | | $ | (9,557) | | |
利息费用,净额
|
| | | | 1,297 | | | | | | 608 | | | | | | 2,232 | | | | | | 1,722 | | |
其他费用
|
| | | | 41 | | | | | | 85 | | | | | | 78 | | | | | | 148 | | |
折旧和摊销
|
| | | | 1,361 | | | | | | 777 | | | | | | 3,231 | | | | | | 2,177 | | |
股票补偿
|
| | | | 733 | | | | | | 268 | | | | | | 1,896 | | | | | | 913 | | |
在我们的首次公开募股时加快限制股票的归属
|
| | | | — | | | | | | — | | | | | | — | | | | | | 1,986 | | |
购置相关费用
|
| | | | 148 | | | | | | — | | | | | | 737 | | | | | | — | | |
调整后的EBITDA
|
| | | $ | 703 | | | | | $ | (127) | | | | | $ | (182) | | | | | $ | (2,611) | | |
|
公开发行每股价格
|
| | | | | | | | | $ | | | |
|
截至2019年9月30日每股有形账面价值
|
| | | $ | 4.20 | | | | | | | | |
|
可归因于投资者购买本次发行股票的每股有形账面净值增加
|
| | | | | | | | | | | | |
|
经调整的截至2019年9月30日每股有形账面价值净额
|
| | | | | | | | | | | | |
|
在本次发行中向新投资者稀释每股股份
|
| | | | | | | | | $ | | | |
| | |
截至2019年9月30日
|
| |||||||||
(单位:千,除分享和每股信息外)
|
| |
实际
|
| |
作为调整
|
| ||||||
现金
|
| | | $ | 19,669 | | | | | $ | | | |
债务总额
|
| | | $ | 51,213 | | | | | $ | | | |
股东权益: | | | | | | | | | | | | | |
普通股,面值0.00025美元;50,000,000股授权;14,967,128股已发行和实际发行;股票发行和发行,经调整
|
| | | | 4 | | | | | | | | |
额外已付资本
|
| | | | 210,479 | | | | | | | | |
累积赤字
|
| | | | (123,393) | | | | | | | | |
累计其他综合收入(损失)
|
| | | | (985) | | | | | | | | |
股东权益总额
|
| | | | 86,105 | | | | | | | | |
总资本化
|
| | | $ | 137,318 | | | | | $ | | | |
| | |
有权受益者
在提供之前 |
| |
股份
赋存 提供 |
| |
有权受益者
供品后 |
| |||||||||||||||||||||
出售股东名称
|
| |
股份
|
| |
%
|
| |
股份
|
| |
%
|
| ||||||||||||||||||
David R.Bailey(1)
|
| | | | 105,721 | | | | | | * | | | | | | 15,000 | | | | | | 90,721 | | | | | | * | | |
Gregory A.Odle(2)
|
| | | | 100,842 | | | | | | * | | | | | | 15,000 | | | | | | 85,842 | | | | | | * | | |
Fred L.Hite(3)
|
| | | | 58,947 | | | | | | * | | | | | | 10,000 | | | | | | 48,947 | | | | | | * | | |
Mark C.Throdahl(4)
|
| | | | 156,773 | | | | | | * | | | | | | 10,000 | | | | | | 146,773 | | | | | | * | | |
承销商
|
| |
数目
股份 |
| |||
Piper Jaffray&Co.
|
| | | | | | |
Stifel,Nicolaus&Company,Instituated
|
| | | | | | |
BTIG公司
|
| | | | | | |
JMP证券有限责任公司
|
| | | | | | |
SunTrust Robinson Humphrey公司
|
| | | | | | |
共计
|
| | | | | |
| | |
每
分享 |
| |
无
期权 |
| |
带着
期权 |
| |||||||||
公开发行价格
|
| | | $ | | | | | $ | | | | | $ | | | |||
承销商折扣
|
| | | $ | | | | | | $ | | | | | | $ | | | |
支出前的收益给我们
|
| | | $ | | | | | | $ | | | | | | $ | | | |
向出售股票的股东收取费用前的收益
|
| | | $ | | | | | | $ | | | | | | $ | | | |
|
骨科儿科公司 |
| |
![]() |
|
| | |
页
|
| |||
关于这份招股说明书
|
| | | | 1 | | |
在其中可以找到更多信息
|
| | | | 2 | | |
引用注册
|
| | | | 3 | | |
公司
|
| | | | 4 | | |
根据本招股说明书提供的产品
|
| | | | 7 | | |
危险因素
|
| | | | 8 | | |
关于前瞻性语句的特别说明
|
| | | | 9 | | |
收益的使用
|
| | | | 10 | | |
股本描述
|
| | | | 11 | | |
债务证券的描述
|
| | | | 16 | | |
认股权证
的描述
|
| | | | 23 | | |
证券的合法所有权
|
| | | | 25 | | |
出售股东
|
| | | | 28 | | |
分配计划
|
| | | | 29 | | |
法律事项
|
| | | | 31 | | |
专家
|
| | | | 31 | | |
| 派珀·贾弗雷 | | | | | |
|
|
| BTIG | | | JMP证券 | | |
SunTrust Robinson Humphrey
|
|